ENGLEWOOD, Colo., March 21, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the Denver Business Journal has ranked Zynex sixth in a list of the largest Denver-area Biotechnology/Bioscience companies, according to the number of full-time employees (FTEs).
"Zynex has experienced significant revenue and order growth over the last several years, and we have invested heavily in the expansion of our quality workforce" said Thomas Sandgaard, CEO and founder of Zynex Inc. "We remain committed to being a high-quality workplace and industry leader in the Denver-area."
About Denver Business Journal
American City Business Journals (ACBJ) is the largest publisher of metropolitan business newsweeklies in the United States, with 44 business publications across the country reaching more than 3.6 million readers each week.
About Zynex, Inc.
Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com
Contact: Zynex, Inc. (800) 495-6670
Investor Relations Contact:
Gilmartin Group
Investor Relations Counsel
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.51 |
| Daily Change: | 0.11 4.58 |
| Daily Volume: | 244,521 |
| Market Cap: | US$79.940M |
June 30, 2025 April 29, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
